article thumbnail

Narcan developer to be acquired by Indivior

Bio Pharma Dive

The deal, which could carry a total value of roughly $145 million, is in large part focused on a nasal formulation of the opioid overdose drug nalmefene

article thumbnail

Rankings: Research and Development

Pharmaceutical Technology

What is Research and Development (R&D)? This category includes organisations that have demonstrated a commitment to the research and development of new products and/or new processes. This category highlights companies that have advanced drug development research.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Black Diamond spins out new biotech to develop cancer drugs

Bio Pharma Dive

Months after restructuring and trimming its workforce, the company has teamed up with its original investors to form an antibody drug developer called Launchpad Therapeutics

Antibody 185
article thumbnail

FDA rejects two China-developed cancer drugs

Bio Pharma Dive

The regulator cited concerns around single-country trials in turning back Hutchmed's pancreatic cancer treatment, while manufacturing issues held up Junshi and Coherus' throat cancer medicine

article thumbnail

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

article thumbnail

UTSA researchers to develop compounds for GBM tumours

Pharmaceutical Technology

A researchers’ team from the University of Texas at San Antonio’s (UTSA) Department of Chemistry and its partners are developing compounds to treat Glioblastoma multiforme (GBM) tumours. The post UTSA researchers to develop compounds for GBM tumours appeared first on Pharmaceutical Technology.

Hormones 207
article thumbnail

Lilly and ProQR to expand genetic medicine development agreement

Pharmaceutical Technology

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.

Genetics 262
article thumbnail

Roche takes over development of Biogen-partnered lymphoma drug

Bio Pharma Dive

Glofitimab, part of a long-standing collaboration between the two companies that’s resulted in Rituxan and Ocrevus, will be the responsibility of Roche, which will pay out royalties

article thumbnail

Visual system brain development implicated in infants who develop autism

Scienmag

Social & Behavioral Science autism brain develop development implicated infants system visual

article thumbnail

Vertex invests in a rare disease drug and its developer

Bio Pharma Dive

The big biotech is paying Entrada Therapeutics $250 million up front to grab rights to an experimental treatment for myotonic dystrophy type 1 in the latest bid to build its pipeline

article thumbnail

Cyagen and Neurophth partner to develop gene therapy vectors

Pharmaceutical Technology

Cyagen and Neurophth Therapeutics have entered a strategic partnership to jointly develop next-generation AAV gene therapy vectors for specific kinds of genetic ophthalmic ailments.

article thumbnail

Capsida Biotherapeutics and Prevail to develop CNS gene therapies

Pharmaceutical Technology

Capsida Biotherapeutics and Eli Lilly and Company ’s wholly owned subsidiary Prevail Therapeutics have announced a partnership for the development of non-invasive gene therapies for central nervous system (CNS) diseases.

article thumbnail

Cloud robotics labs are accelerating drug discovery and development

Pharmaceutical Technology

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development.

article thumbnail

Astellas takes stake in gene therapy developer Taysha

Bio Pharma Dive

Already an investor in gene therapy, the Japanese pharma will buy 15% of the Texas biotech’s stock and gain options to two gene therapies for central nervous system disorders

article thumbnail

Eisai and Washington University to develop neurodegenerative disease therapies

Pharmaceutical Technology

Eisai has entered a comprehensive research partnership agreement with Washington University School of Medicine in St Louis, US, to develop potential new therapies for neurodegenerative ailments.

article thumbnail

Umoja and IASO partner to develop therapies for haematological malignancies

Pharmaceutical Technology

Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies. The post Umoja and IASO partner to develop therapies for haematological malignancies appeared first on Pharmaceutical Technology.

In-Vivo 227
article thumbnail

Kite and Arcellx enter partnership for multiple myeloma therapy development

Pharmaceutical Technology

Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients.

article thumbnail

Prevail, Capsida partner to develop gene therapies for nervous system diseases

Bio Pharma Dive

The Lilly-owned subsidiary will pay $55 million to gain access to Capsida’s AAV gene therapy technology in a deal aimed at central nervous system disorders

article thumbnail

Qurient partners with TB Alliance to develop telacebec

Pharmaceutical Technology

South Korean biotechnology company Qurient has entered a licence agreement with TB Alliance for the development and commercialisation of telacebec (Q203). It will be developed to treat tuberculosis (TB) and other non-tuberculosis mycobacteria (NTM) infections.

Drugs 130
article thumbnail

Merck and Moderna partner to develop and sell cancer vaccine

Pharmaceutical Technology

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs.

article thumbnail

Tetra and Cellvera partner to develop oral Covid-19 treatment

Pharmaceutical Technology

Tetra Bio-Pharma and Cellvera have entered an agreement to jointly develop ARDS-003 as an oral combination therapeutic candidate with 400mg Qifenda (Favipiravir) for Covid-19. Developed by FujiFilm Toyama Chemical, Favipiravir is currently owned by Cellvera.

RNA 264
article thumbnail

Boost agility and speed in your drug development research

Bio Pharma Dive

How flexible API access to integrated 'omics data helps boost agility and speed in drug research

article thumbnail

Novartis confirms it has stopped development of experimental Huntington’s drug

Bio Pharma Dive

Termination of the branaplam program, according to Novartis, was due to an “overall assessment of the risk-benefit profile” observed in a mid-stage clinical trial that raised safety concerns last year

article thumbnail

2022 in review: Drug development milestones for tropical diseases

Pharmaceutical Technology

Previously disrupted by the Covid-19 pandemic, this past year has seen a return of increased efforts and progress in the development of new treatments for tropical diseases. We ourselves took up activities related to developing Covid-19 vaccines,” says Duffy.

article thumbnail

AlzeCure begins Alzheimer's therapy development phase

Pharma Times

Candidate will go through the development programme, which includes safety and tolerability studies

article thumbnail

Hookipa partners with Roche for cancer immunotherapy development

Pharmaceutical Technology

Hookipa Pharma and Roche have signed a strategic partnership and licence agreement for developing HB-700 and another undisclosed arenaviral immunotherapy. Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers.

article thumbnail

Astellas to support development of Taysha’s gene therapy programmes

Pharmaceutical Technology

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN).

article thumbnail

Lilly agrees to acquire gene therapy developer Akouos for $610m

Pharmaceutical Technology

Akouos focuses on developing adeno-associated viral gene therapies to treat inner ear conditions, including sensorineural hearing loss. The post Lilly agrees to acquire gene therapy developer Akouos for $610m appeared first on Pharmaceutical Technology.

article thumbnail

Merck stops coronavirus vaccine development in surprise setback

Bio Pharma Dive

The drugmaker, one of the largest vaccine developers globally, won't move forward with either of two candidates it's been testing after disappointing data in early trials

article thumbnail

Supporting multi-audience communication in all stages of drug development

Bio Pharma Dive

Biopharmaceutical companies have ongoing and extensive needs for print and digital communications throughout the drug development life cycle that can benefit from a single-source vendor

article thumbnail

JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies

Bio Pharma Dive

Moderna’s Stéphane Bancel and Pfizer’s Albert Bourla hinted Monday at greater dealmaking to come for their companies, while Gilead gave investors an update on an important cancer drug trial

article thumbnail

Alzheimer’s disease biomarkers galvanise rocky drug development space

Pharmaceutical Technology

Alongside the discourse on what the positive study results could mean for patients, researchers are prioritising the development of more biomarkers to identify potential responders and improve patient outcomes.

article thumbnail

FDA and NIH partner for neurodegenerative disease treatment development

Pharmaceutical Technology

The US Food and Drug Administration (FDA) and the US National Institutes of Health (NIH) have unveiled a public-private partnership (PPP) to understand and develop treatments for neurodegenerative diseases.

article thumbnail

FDA sets out advice to developers of gene editing medicines

Bio Pharma Dive

Draft recommendations from the agency were generally straightforward, analysts said, although the document emphasized the potential safety risks of gene editing

article thumbnail

Bain Capital backs new biotech startup developing oral asthma drug

Bio Pharma Dive

Areteia Therapeutics will receive $350 million from Bain and others to advance a drug that was previously licensed to Biogen for testing as an ALS treatment

Licensing 228
article thumbnail

ElevateBio and Affini-T collaborate to develop T cell therapies

Pharmaceutical Technology

Under the deal, the LentiPeak lentiviral vector technology platform and cell therapy production expertise of ElevateBio BaseCamp will be used by Affini-T to develop its investigational oncogenic driver programmes in the clinic.

article thumbnail

Lonza expands team, labs for cell and gene development

BioPharma Reporter

Lonza is to increase the size of the cell and gene therapy (CGT) development space at its Houston facility; the expansion will include viral vector-based process development and analytical development laboratories. Bio Developments

article thumbnail

MD Anderson partners with Federation Bio to develop microbiome therapy

Pharmaceutical Technology

The University of Texas MD Anderson Cancer Center has announced a strategic collaboration with Federation Bio for the development of a new microbiome treatment for immunotherapy-resistant cancer patients.

Bacteria 130
article thumbnail

In the News: November 2021 Regulatory and Development Updates

Camargo

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. 505(b)(2) Development Blog In the News Pediatrics Regulatory Strategy & Submissions

article thumbnail

Alzheimer’s disease biomarkers galvanize rocky drug development space

Pharmaceutical Technology

Alongside the discourse on what the positive study results could mean for patients, researchers are prioritising the development of more biomarkers to identify potential responders and improve patient outcomes.

article thumbnail

Vaccine Developers of the Year: BioNTech and Moderna

Bio Pharma Dive

Defying expectations, BioNTech and Moderna each designed and developed highly effective coronavirus shots far faster than previously considered possible

article thumbnail

In the News: August 2021 Regulatory and Development Updates

Camargo

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. In the News: August 2021 Regulatory and Development Updates.

article thumbnail

ALS drug approved by FDA in closely watched decision, marking win for patients, developer

Bio Pharma Dive

The drug, which will be sold as Relyvrio, showed modest benefits in function and survival in testing. It also became the latest test of the FDA's flexibility toward new therapies for neurological disorders